EGFR and non-small cell lung carcinoma: Of note, the combination of erlotinib with either bevacizumab or ramucirumab is approved as first-line therapy for the treatment of patients with NSCLC harboring canonical EGFR mutations (Del19 or L858R) in Europe and the USA, respectively.